Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 3, Issue 6, 2000, Pages 417-424

  Sole, Michael J ^a   Jeejeebhoy, Khursheed N ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CARNITINE; CREATINE; TAURINE; THIAMINE; UBIDECARENONE;

AMINO ACID METABOLISM; CALCIUM CELL LEVEL; CONGESTIVE HEART FAILURE; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; ENERGY EXPENDITURE; ENERGY TRANSFER; HUMAN; NUTRITIONAL SUPPORT; OXIDATIVE STRESS; PATHOGENESIS; REGULATORY MECHANISM; REVIEW; VITAMIN METABOLISM;

CALCIUM; DIETARY SUPPLEMENTS; ENERGY METABOLISM; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIUM; NUTRITION ASSESSMENT; NUTRITION DISORDERS; NUTRITIONAL REQUIREMENTS; NUTRITIONAL SUPPORT; OXIDATIVE STRESS;

EID: 0033634980     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-200011000-00001     Document Type: Review

References (77)

1. Epidemiology of heart failure in the United States
2. Epidemiology of heart failure in Europe
3. Shifting the paradigm for the treatment of dilated cardiomyopathy
4. The myocardium in congestive heart failure
5. Heart failure: Is there an energy deficit contributing to contractile dysfunction?
6. Is cardiac failure a consequence of decreased energy reserve?
7. Muscle fatigue and dyspnoea in chronic heart failure: Two sides of the same coin?
8. The nutrition implications of cardiac cachexia
9. Prevalence and hemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
10. Daily energy expenditure in freeliving heart failure patients
11. Nutritional assessment and muscle energy metabolism in severe chronic congestive heart failure: Effects of long-term dietary supplementation
12. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia
13. Carnitine and its derivatives in cardiovascular disease
14. Propionyl L-carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation
15. The therapeutic potential of carnitine in cardiovascular disorders
16. Carnitine deficiency syndromes and lipid storage myopathies
17. L-carnitine treatment improves cardiac performance and restores high-phosphate pools in cardiomyopathic Syrian hamster
18. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: The L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trial
19. Coenzyme Q reductase from liver plasma membrane: Purification and role in trans-plasma-membrane electron transport
20. Coenzyme Q10, plasma membrane oxidase and growth control
21. An updating of the biochemical function of coenzyme Q in mitochondria
22. Lovastatin decreases coenzyme Q levels in humans
23. Effects of mevinolin treatment on tissue dolichol and ubiquinone levels in the rat
24. Plasma levels of coenzyme Q10 before and after oral supplementation: A bioavailability study
25. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10
26. Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant
27. The effect of treatment with coenzyme Q10 on the mitochondrial function and superoxide radical formation in cardiac muscle hypertrophied by mild aortic stenosis
28. Coenzyme Q10 attenuates the progression of cardiomyopathy in hamsters
29. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10
30. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy
31. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure
32. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure
33. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analysis of clinical trials
34. Thiamine deficiency in hospitalized elderly patients
35. Clinical signs in the Wernicke-Korsakoff complex: A retrospective analysis of 131 cases diagnosed at necropsy
36. The sequence of metabolic, clinical and histological reversibility of thiamine deficiency
37. Apoptosis is restricted to the thalamus in thiamine-deficient rats
38. Thiamine status, diuretic medications and the management of congestive heart failure
39. Furosemide induced thiamine deficiency
40. Thiamine deficiency in patients with congestive failure receiving long-term furosemide therapy: A pilot study
41. Thiamine status of elderly patients with cardiac failure including the effects of supplementation
42. Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy
43. 1-4 Creatine metabolism and the consequences of creatine depletion in muscle
44. Creatine kinase system in failing and nonfailing human myocardium
45. 2+ handling and survival in mdx skeletal muscle cells
46. In patients with cardiomyopathy the myocardial phosphocreatine/ATP ratio predicts mortality better than ejection fraction or NYHA class
47. Mitral regurgitation: Impaired systolic function eccentric hypertrophy and increased severity are linked to lower phosphocreatine/ATP ratios in humans
48. Creatine in humans with special reference to creatine supplementation
49. Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans
50. Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance
51. The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure
52. Calcium improves mechanical function and carbohydrate metabolism following ischemia in isolated bi-ventricular working hearts from immature rabbits
53. Intramitochondrial protein synthesis is regulated by matrix adenine nucleotide content and requires calcium
54. Usefulness of taurine in chronic congestive heart failure and its prospective application
55. Review of some actions of taurine on ion channels of cardiac muscle cells and others
56. Conversion of taurine into N-chlorotaurine (taurine chloramine) and sulphoacetaldehyde in response to oxidative stress
57. Reactivity of taurine with aldehydes and its physiological role
58. Physiological and experimental regulation of taurine content in the heart
59. Taurine in development
60. Expression and regulation of the taurine transporter in cultured cell lines of human origin
61. Loss of cardiac muscle taurine after acute left ventricular ischemia
62. Potentation of myocardial ischemic injury by drug-induced taurine depletion
63. Alterations of ventricular contractility and myofibrillar loss in taurine deficient hearts
64. Myocardial failure in cats associated with low plasma taurine: A reversible cardiomyopathy
65. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure
66. Increased oxidative stress in patients with congestive heart failure
67. Cysteine and glycine supplementation modulate the metabolic response to tumor necrosis factor alpha in rats fed a low protein diet
68. The effect of taurine on calcium paradox and ischemic heart failure
69. Taurine decreases lesion severity in the hearts of cardiomyopathic Syrian hamsters
70. Beneficial effect of taurine in rabbits with chronic congestive heart failure
71. Oxidative stress and the pathogenesis of heart failure
72. Oxidative stress and heart failure
73. Vitamin E and oxidative stress in the heart of the cardiomyopathic Syrian hamster
74. Increased malondialdehyde in peripheral blood of patients with congestive heart failure
75. Oxy free radical system in heart failure and therapeutic role of vitamin E
76. A controlled clinical trial of vitamin E supplementation in patients with congestive cardiac failure